131 Oyster Point Blvd, Suite 200
South San Francisco
About Maze Therapeutics
Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations.
What are genetic modifiers?
Despite an understanding of the genetic basis for many diseases, it remains a mystery why some people with a disease-causing mutation never get sick. This is often due to genes elsewhere in our DNA that affect the severity of disease and can provide a natural form of protection.
The Maze approach
Dramatic advances in human genetics and functional genomics now enable us to decode the mysteries of genetic modifiers in a range of severe diseases. Today, we believe we can systematically identify genetic modifiers and turn these insights into medicines. We have assembled a world-class team to realize this vision, including creative scientific pioneers, experienced company builders and biotech industry leaders.
Join us in our pursuit to change lives by translating genetic insights into medicine - view our job postings with the link to the left.
7 articles with Maze Therapeutics
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Maze Therapeutics, a company focused on translating genetic insights into new medicines, announced that Jonathan Lim, M.D., founder and managing partner at City Hill Ventures, has joined the company’s board of directors.
Maze Therapeutics Appoints Drug Development Expert Richard Scheller, Ph.D., to its Board of Directors
Dr. Scheller was previously the head of therapeutics and chief scientific officer at 23andMe.
Maze Therapeutics, a company focused on translating genetic insights into new medicines, today announced that Jason Coloma, Ph.D., Maze’s current chief operating officer, has been appointed as chief executive officer.
Maze Therapeutics Launches with $191 Million to Focus on Translating Genetic Insights into New Medicines
Third Rock Ventures announced the launch of Maze Therapeutics, a company focused on translating genetic insights into new medicines.
The company will focus on what are dubbed modifier genes. Essentially, two people with the same disease-causing genetic mutations often show varying degrees of illness, or in some cases, none at all.